Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Eitner

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
The American Journal of Pathology|August 6, 1999
Thrombotic microangiopathy in the HIV-2-infected macaqueF Eitner, Y Cui, K L Hudkins, et al.
Kidney International|October 5, 2007
CCN3 is a novel endogenous PDGF-regulated inhibitor of glomerular cell proliferationC R C van Roeyen, F Eitner, T Scholl, et al.
The American Journal of Pathology|April 7, 2000
Rapid shift from virally infected cells to germinal center-retained virus after HIV-2 infection of macaquesF Eitner, Y Cui, G Grouard-Vogel, et al.
The New England Journal of Medicine|June 7, 2013
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndromeC M Legendre, C Licht, P Muus, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
The American Journal of Pathology|August 6, 1999
Thrombotic microangiopathy in the HIV-2-infected macaqueF Eitner, Y Cui, K L Hudkins, et al.
Kidney International|October 5, 2007
CCN3 is a novel endogenous PDGF-regulated inhibitor of glomerular cell proliferationC R C van Roeyen, F Eitner, T Scholl, et al.
The American Journal of Pathology|April 7, 2000
Rapid shift from virally infected cells to germinal center-retained virus after HIV-2 infection of macaquesF Eitner, Y Cui, G Grouard-Vogel, et al.
The New England Journal of Medicine|June 7, 2013
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndromeC M Legendre, C Licht, P Muus, et al.
Pageof 3